Table 3.
General data of the rats used in the study after 12 weeks of treatment (mean ± SEM)a
| Characteristics | NC (n=10) | DM (n=10) | DTL (n=10) | DTH (n=10) |
|---|---|---|---|---|
| ISI | 0.221±0.024 | 0.052±0.004* | 0.060±0.005* | 0.059±0.004* |
| FINS ng/ml | 18.57±1.01 | 22.09±1.75 | 20.16±1.57 | 20.49±1.61 |
| FBG mmol/L | 5.56±0.64 | 19.44±0.47* | 18.58±0.58* | 18.55±0.52* |
| TG mmol/L | 1.49±0.15 | 4.83±0.69* | 4.42±0.48* | 4.30±0.70* |
| TC mmol/L | 0.76±0.24 | 3.99±0.25* | 3.78±0.26* | 3.75±0.34* |
| AST U/L | 47.8±4.57 | 48.9±4.12 | 48.2±3.45 | 47.9±5.04 |
| ALT U/L | 42.9±3.54 | 44.1±3.60 | 43.2±3.29 | 43.1±3.14 |
a
ISI: insulin sensitivity index; FINS: Fasting serum insulin; FBG: Fasting blood glucose; TC: Total cholesterol; TG: Triglyceride; AST: aspartate aminotransferase; ALT: alanine aminotrans; NC: Control group; DM: Type 2 diabetes model group; DTL: valsartan group; DTH:
*
P<0.05 (compared with the NC group).